Overview

1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determinate progression free survival after 9 months of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Unidad Integral de Investigación en Oncología S.L.
Collaborator:
Hoffmann-La Roche
Treatments:
Bevacizumab
Capecitabine
Oxaliplatin